<qa>  What is the name of the subset of patients with HER2neu overexpressing stage II- Evaluate the probability of achieving a pathological complete remission when adding trastuzumab Herceptin to ACAC in the subset of patients with HER2neu overexpressing stage II or III breast cancer. 